Celera Corp. (CRA) reported break-even earnings in the third-quarter, compared to the Zacks Consensus Estimate of a loss of 6 cents. The company earned a cent in the year-ago quarter.

Net revenues for the quarter came in at $40 million as against $45.8 million in the year-ago quarter. Segment wise revenues from lab services were $24.2 million compared to $30.1 million in the year-ago quarter, primarily because of lower reimbursement rates. Revenues from products came in at $10.0 million compared to $10.5 million in the prior year quarter. Revenues for the quarter were primarily from sales of Celera-manufactured products and royalties from sales of RealTime assays used on the m2000 system from Abbott Molecular, a subsidiary of Abbott Laboratories (ABT). Corporate revenues for the quarter came in at $5.8 million as against $5.2 million in the prior year quarter. The $0.6 million increase was primarily attributable to the inclusion of revenues from one of Celera’s licensees Cepheid (CPHD) in the reported quarter which was partially offset by lower revenues from other licensees.

Research & Development spend in the quarter decreased to $6.2 million from $7.9 million in the year-ago quarter because of the completion of certain research and development projects and associated lower employee-related costs in the corporate and products segments in addition to the termination of the strategic alliance with Abbott. Selling general & administrative expenses for the quarter came in at $22.6 million compared to $25.2 million in the year-ago quarter.

Celera exited the quarter with cash and short-term investments of approximately $321 million, compared to approximately 320 million at June 27, 2009.

The company expects to incur a loss of 5 cents to 7 cents in the next quarter. Celera forecasts total revenues to be between $163 million and $167 million in 2009.

Currently, we are Neutral on Celera.

Zacks Investment Research
View original at: Zacks.com News Feed

1. (HAE) Haemonetics Corporation Reports Strong Earnings ResultsHaemonetics Corporation (HAE) reported strong results for the second quarter of fiscal 2010. Earnings per...
2. (OCLR) Oclaro Posts Earnings In-Line In The QuarterOclaro Inc. (OCLR) recently reported revenues of $85.1 millionin the first quater of 2010, up...
3. (SEH) Spartech Corporation Posts Lackluster Q3Spartech Corp. (SEH) recently posted lackluster third-quarter results as recessionary conditions affected demand for its...
4. (MOVE) Move, Inc. – 2 cents easily beat the estimate of break-even earningsMove, Inc. (MOVE) recently reported sales of $54.6 million in the second quarter of 2009,...
5. (CRA) Celera Corporation – consensus estimates are relatively through the roofCelera Corp. (CRA) is showing phenomenal growth over the next few years as shares continue...
6. (GEOY) GeoEye: It’s Make or Break Time, LiterallyLike one of its satellites racing overhead for some amazing and spectacular shots of the...

Search Posts by Tag: Abbott Laboratories | ABT | Celera Corporation | Cepheid | CPHD | CRA | Scientific & Technical Instruments | Technology

RSS Feeds by Tag: Abbott Laboratories | ABT | Celera Corporation | Cepheid | CPHD | CRA | Scientific & Technical Instruments | Technology |

Other Posts by: vitalstocks | RSS Feed for this author